Literature DB >> 45

Bovine liver dihydrofolate reductase: purification and properties of the enzyme.

D L Peterson, J M Gleisner, R L Blakley.   

Abstract

A purification procedure is reported for obtaining bovine liver dihydrofolate reductase in high yield and amounts of 100-200 mg. A key step in the procedure is the use of an affinity gel prepared by coupling pteroyl-L-lysine to Sepharose. The purified reductase has a specific activity of about 100 units/mg and is homogeneous as judged by analytical ultracentrifugation, polyacrylamide gel electrophoresis, and titration with methotrexate. The products of the first step of Edman degradation indicated a minimum purity of 79%. The reductase has a molecular weight of about 21500 on the basis of amino acid composition and 22100 +/- 300 from equilibrium sedimentation. It is not inhibited by antiserum to the Streptococcus faecium reductase (isoenzyme 2). Unlike the reductase of many other vertebrate tissues, the bovine enzyme is inhibited by mercurials rather than activated and it has a single pH optimum at both low and high ionic strength. However, the position of the pH optimum is shifted and the activity increased by increasing ionic strength. Automatic Edman degradation has been used to determine 34 of the amino-terminal 37 amino acid residues. Considerable homology exists between this region and the corresponding regions of the reductase from S. faecium and from Escherichia coli. This strengthens the idea that this region contributes to the structure of the binding site for dihydrofolate.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 45     DOI: 10.1021/bi00695a005

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Synthesis of site-specific methotrexate-IgG conjugates. Comparison of stability and antitumor activity with active-ester-based conjugates.

Authors:  J Kralovec; M Singh; M Mammen; A H Blair; T Ghose
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Inhibition of folate enzymes by sulfasalazine.

Authors:  J Selhub; G J Dhar; I H Rosenberg
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

3.  Recombinant bovine dihydrofolate reductase produced by mutagenesis and nested PCR of murine dihydrofolate reductase cDNA.

Authors:  Vivian Cody; Qilong Mao; Sherry F Queener
Journal:  Protein Expr Purif       Date:  2008-07-17       Impact factor: 1.650

4.  Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen.

Authors:  T Ghose; S Ferrone; A H Blair; Y Kralovec; M Temponi; M Singh; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Conjugation of methotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo.

Authors:  P N Kulkarni; A H Blair; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Maintenance of dihydrofolate reductase enzyme after disappearance of DHFR mRNA during muscle cell differentiation.

Authors:  E E Schmidt; G F Merrill
Journal:  In Vitro Cell Dev Biol       Date:  1989-08

7.  Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites.

Authors:  P O Uadia; A H Blair; T Ghose
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model.

Authors:  M Singh; T Ghose; J Kralovec; A H Blair; P Belitsky
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.